Pro: Aprotinin should be used in patients undergoing hypothermic circulatory arrest

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 15, Issue 1, 2001, Pages 121-125

  Royston, David ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Aortic surgery; Aprotinin; Coagulation problems; Inflammatory responses

Indexed keywords

APROTININ;

BLEEDING; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART ARREST; HUMAN; HYPOTHERMIA; KIDNEY FAILURE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0035114126     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2001.20351     Document Type: Article

References (54)

1. A case for aprotinin in patients having deep hypothermic circulatory arrest
2. Aprotinin in deep hypothermic circulatory arrest
3. Operations on the thoracic aorta and hypothermic circulatory arrest: Is aprotinin safe?
4. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations
5. Preventing the inflammatory response to open-heart surgery: The role of aprotinin and other protease inhibitors
6. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass
7. Aprotinin versus lysine analogues: The debate continues
8. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs
9. Aprotinin improves myocardial recovery after ischemia and reperfusion: Effects of the drug on isolated rat hearts
10. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations
11. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage
12. Release of cardiac troponin I in antegrade crystalloid versus cold blood cardioplegia
13. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest
14. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermic circulatory arrest
15. Aprotinin and bleeding in profoundly hypothermic perfusion
16. Deep hypothermia with circulatory arrest: Determinants of stroke and early mortality in 656 patients
17. Increased anticoagulation during cardiopulmonary bypass by aprotinin
18. Reduced blood loss following open heart surgery with aprotinin (Trasylol) is associated with an increase in intraoperative activated clotting time (ACT)
19. High-dose aprotinin therapy: A review of the first five years' experience
20. Aprotinin and heparin monitoring during cardiopulmonary bypass
21. Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest
22. Aprotinin in perspective
23. Coagulation disturbance in profound hypothermia: The influence of antifibrinolytic therapy
24. Safety and efficacy of aprotinin in profoundly hypothermic circulatory arrest
25. Anti-fibrinolytic therapy in thoracic aortic surgery
26. Aprotinin does not inhibit the release of PGI2 or vWF from cultured human endothelial cells
27. Aprotinin (Trasylol) is a competitive inhibitor of activated protein C
28. Inhibition of activated protein C by aprotinin and the use of the insolubilized inhibitor for its purification
29. Does aprotinin influence endothelial-associated coagulation in cardiac surgery?
30. Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations
31. The effect of the anticoagulation regimen on endothelial-related coagulation in cardiac surgery patients
32. The role of protein C as an inhibitor of blood clotting during extracorporeal circulation
33. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis
34. Use of aprotinin therapy in a patient with factor V Leiden
35. Cardiac transplantation in a patient with protein S deficiency
36. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex
37. Inhibition of the cold activation of factor VII and the prothrombin time
38. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass
39. Replacement of the thoracic aorta with collagen-impregnated woven Dacron grafts. Early results
40. A case of bacteremia and disseminated intravascular coagulation after the conduit procedure for tetralogy of Fallot with pulmonary atresia
41. Early changes of the coagulation system in multiple injuries and their modification with heparin and Trasylol
42. Intravascular coagulation and fibrinolysis syndrome (ICF) in acute non-promyelocytic leukemia
43. The protease inhibitor treatment of the disseminated intravascular coagulation syndrome in patients with liver cirrhosis
44. Orthotopic liver transplant for giant cavernous hemangioma and Kasabach-Merritt syndrome
45. Hyperfibrinolysis during intracranial surgery: Effect of high-dose aprotinin
46. Treatment of obstetrical disseminated intravascular coagulation - Sequential changes of coagulation and fibrinolytic system in DIC rabbits
47. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol)
48. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass
49. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
50. Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function
51. Influence of haemoglobin concentration after extracorporeal circulation on mortality and morbidity in patients undergoing cardiac surgery
52. Use of aprotinin in LVAD recipients reduces blood loss, blood use and perioperative mortality
53. Risk factors for acute postoperative renal failure in thoracic or thoracoabdominal aortic surgery: A prospective study
54. Aprotinin versus epsilon-aminocaproic acid for aortic surgery using deep hypothermic circulatory arrest